STAFF WRITERS
THE latest treatment for Gippslanders who suffer from severe eczema is now available locally thanks to a recently-opened dermatology clinical trial.
The trial, which is also currently running in the US and Canada, is testing a new treatment for moderate to severe eczema.
Latrobe Regional Health (LRH) is the first non-metro hospital in the world to open this trial, which has been made possible by sharing care together with The Alfred Hospital through a new model called a teletrial.
A teletrial is where hospitals and healthcare providers work together as one team to deliver the same clinical trial across more than one hospital.
The model means regional and rural patients can access clinical trials closer to home, reducing the mental and financial burden of often having to travel hours to metro centres for treatment.
This is the first dermatology clinical trial to open in the region. Local staff have been given the opportunity to be upskilled by The Alfred Hospital’s dermatology team, who will also oversee care throughout the clinical trial.
Patients will still have to travel to Melbourne for some appointments, but the majority of care is closer to home, thus reducing travel.
LRH General Manager of Research and Partnerships Dr Jhodie Duncan said the teletrial model has enabled the hospital to open more trials that can give locals access to potentially life-saving treatment and improved quality of life without having to travel to Melbourne.
“This is a relatively new model for us in Victoria, but we hope to embed it into our practice as it enhances our ability to provide better care for regional patients,” Dr Duncan said.
“Teletrials give us an opportunity to open clinical trials that we may not have the capacity to run on our own.”
The trial is being overseen by Alfred Health’s Head of Dermatology, Professor Johannes Kern.
“This (severe eczema) is a chronic, life-long disease that can significantly impact a person’s quality of life,” Professor Kern said.
“Despite available treatment options, not all patients with moderate-to-severe atopic dermatitis respond sufficiently to current treatments, and many continue to suffer.
“We are thrilled at the possibility of uncovering the latest treatment, and that for the first-time, regional patients can now participate without having to come into The Alfred for the entire clinical trial.
“This is an incredible milestone not only for patients in Gippsland, but it shows what is now possible for other regional patients across Australia.”
Clinical trials give people access the latest treatment well before they are available to the general public.
If you would like to be considered for this trial or to learn more about other available trials, go to lrh.com.au/research or email clinicaltrials@lrh.com.au
